Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Phase 3 CORALreef Lipids Trial  Merck.com Merck PCSK9 Pill Results Point to Extremely Low Cholesterol Future  The New York Times New pill cuts LDL cholesterol by 60 per cent, show trials: Cardiologists break down if it can reduce heart attacks  The Indian Express Experimental daily pill may lower cholesterol in patients who don’t see enough benefit with statins alone, study finds  CNN Merck’s pill to reduce cholesterol on top of statins matches results from injectables  statnews.com